This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.

Inclusion Criteria:

• Patients between 18 and 80 years old, with no gender restrictions.
• Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
• Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.

Exclusion Criteria:

• Expected survival time<12 months;
• Severe liver dysfunction (non heart disease induced ALT or AST>3x ULN) and cirrhosis;
• Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
• The researchers determined that other reasons were not suitable for participants in this experiment.